Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.

被引：0
|
作者：
Saunders, Mark P.
Lang, Istvan
Marcuello, Eugenio
Lorusso, Vito
Ocvirk, Janja
Shin, Dongbok
Jonker, Derek J.
Osborne, Stuart
Loeffler, Markus
Waterkamp, Daniel
Cunningham, David
机构：
[1] Christie Hosp NHS Fdn Trust, Withington, England
[2] Natl Inst Oncol, Budapest, Hungary
[3] Hosp St Pau Barcelona, Barcelona, Spain
[4] Vito Fazzi Hosp, Inst Oncol, Bari, Italy
[5] Inst Oncol Ljubljana, Ljubljana, Slovenia
[6] Gachon Univ, Gil Hosp, Dept Internal Med, Inchon, South Korea
[7] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[8] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[9] Royal Marsden Hosp NHS Fdn Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3521
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?
    Omrcen, T.
    Katic, A.
    Tomic, S.
    Eterovic, D.
    Vrdoljak, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] RETROSPECTIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH BIWEEKLY XELIRI AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Garcia Alfonso, P.
    Alvarez Suarez, S.
    Munoz Martin, A.
    Gonzalez del Val, R.
    Gutirrez Cabezon, L.
    Jerez Gilarranz, Y.
    Marquez-Rodas, I.
    Soria Lobelle, A.
    Riesco Martinez, M. C.
    Adeva Alfonso, J.
    ANNALS OF ONCOLOGY, 2010, 21 : I50 - I50
  • [33] NICE guidance on bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
    Umeweni, Nwamaka
    Nolan, Kay
    Knight, Helen
    Clark, Peter
    LANCET ONCOLOGY, 2012, 13 (10): : 977 - 978
  • [34] Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    Tebbutt, Niall C.
    Wilson, Kate
    Gebski, Val J.
    Cummins, Michelle M.
    Zannino, Diana
    van Hazel, Guy A.
    Robinson, Bridget
    Broad, Adam
    Ganju, Vinod
    Ackland, Stephen P.
    Forgeson, Garry
    Cunningham, David
    Saunders, Mark P.
    Stockler, Martin R.
    Chua, YuJo
    Zalcberg, John R.
    Simes, R. John
    Price, Timothy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : 3191 - 3198
  • [35] A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer
    Wainberg, Zev
    Hecht, J. Randolph
    CLINICAL COLORECTAL CANCER, 2006, 5 (05) : 363 - 367
  • [36] Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer
    Grande, Carlos
    Quintero, Guillermo
    Candamio, Sonia
    Paris Bouzas, Lorena
    Jose Villanueva, Maria
    Campos, Begona
    Gallardo, Elena
    Alvarez, Elena
    Casal, Joaquin
    Ramon Mel, Jose
    JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (02) : 114 - 121
  • [37] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
    Saltz, Leonard B.
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Cassidy, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2013 - 2019
  • [38] Activity and safety of vinorelbine and capecitabine as first-line treatment in patients with metastatic breast cancer - a phase II trial
    Palumbo, R.
    Bernardo, A.
    Strada, M.
    Teragni, C.
    Poggi, G.
    Frascaroli, M.
    Amatu, A.
    Palumbo, I.
    Bernardo, G.
    EJC SUPPLEMENTS, 2008, 6 (07): : 177 - 177
  • [39] Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
    Sledge, G.
    Miller, K.
    Moisa, C.
    Gradishar, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer.
    Vanhoefer, UJ
    Mayer, S
    Achterrath, W
    Hense, J
    Omidi, S
    Frings, S
    Harstrick, A
    Wilke, H
    Seeber, S
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
12345